Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced Melanoma

Source: OncLive, July 2021

Sajeve Samuel Thomas, MD, medical oncologist and hematologist, Orlando Health Cancer Institute, Orlando Health, assistant professor, Florida State University College of Medicine and University of Central Florida College of Medicine, discusses the safety profile of lifileucel (LN-144) plus pembrolizumab (Keytruda) in advanced melanoma.

The results of the ongoing phase 2 IOV-COM-202 trial (NCT03645928), which were presented during the 2021 ASCO Annual Meeting, demonstrated early efficacy signals with the combination of lifileucel, a tumor-infiltrating lymphocyte cellular therapy, and pembrolizumab in patients with checkpoint inhibitor–naïve advanced melanoma.

READ THE ORIGINAL FULL ARTICLE